Skip to main content

Table 3 Results (n = 70)

From: Salvage radiotherapy for recurrent hypopharyngeal and laryngeal squamous cell carcinoma (SCC) after first-line treatment with surgery alone: a 10-year single-centre experience

characteristics 5-year survival univariate analysis multivariate analysis
HR (95%-KI) p value HR (95%-KI) p value
overall survival
at first-line treatment (surgery)
iT stage (T3/4 vs. T1/2) 45% vs. 72% 1.46 (1.01–2.11) 0.041  
iN stage (N+ vs. N0) 25% vs. 78% 5.78 (2.66–12.59) 0.000 2.50 (0.96–6.49) 0.060
at second-line treatment (RT/CRT)
recurrent tumor site (others vs.
glottis) 42% vs. 89% 4.70 (1.79–12.33) 0.001 4.77 (1.00–22.70) 0.050
rKPS (≥90% vs. <  90%) 68% vs. 36% 0.55 (0.35–0.84) 0.050  
chemotherapy (others vs. cisplatin weekly) 35% vs. 64% 2.37 (1.04–5.45) 0.035  
local recurrence after RT
(yes vs. no) 25% vs. 74% 3.10 (1.44–6.67) 0.002 2.63 (1.04–6.69) 0.041
metastases after RT (yes vs. no) 3% vs. 70% 3.44 (1.54–7.71) 0.001  
local progression-free survival
at first-line treatment (surgery)
iN stage (N+ vs. N0) 50% vs. 86% 4.52 (1.60–12.72) 0.002 3.62 (0.92–14.19) 0.065
iG stage (G3 vs. G1/2) 59% vs. 82% 2.77 (1.00–7.66) 0.038  
at second-line treatment (RT/CRT)
rG stage (G3 vs. G1/2) 59% vs. 82% 2.66 (1.04–7.80) 0.036  
EQD2 (> 70 Gy vs. =70 Gy) 90% vs. 68% 0.25 (0.06–1.10) 0.045 0.10 (0.01–0.82) 0.032
chemotherapy (others vs. cisplatin weekly) 46% vs. 86% 5.78 (1.75–19.13) 0.001 3.62 (0.92–14.19) 0.006
distant progression-free survival
at first-line treatment (surgery)
iN stage (N+ vs. N0) 40% vs. 89% 6.19 (1.85–20.76) 0.001 2.56 (1.03–6.34) 0.042
iG stage (G3 vs. G1/2) 65% vs. 85% 3.06 (1.03–9.13) 0.035 3.45 (0.98–12.23) 0.055
at second-line treatment (RT/CRT)
rT stage (T3/4 vs. T1/2) 70% vs. 90% 3.30 (0.91–11.99) 0.055 6.02 (1.29–30.00) 0.028
rG stage (G3 vs. G1/2) 65% vs. 85% 3.12 (1.00–9.25) 0.037 3.45 (0.98–12.23) 0.054
recurrent tumor site (others vs.
glottis) 68% vs. 100% 6.02 (0.68–10.24) 0.014  
PTV1 volume (=median vs.
<median of 101 cc) 65% vs. 87% 3.85 (1.04–14.22) 0.030 5.39 (1.65–12.53) 0.038
chemotherapy (others vs. cisplatin weekly) 57% vs. 82% 3.27 (1.03–10.41) 0.034  
  1. abbreviations: EQD2 equivalent dose to 2 Gy single fraction, HR hazard ratio, iT stage initial tumor stage, iN stage initial nodal stage, KPS Karnofsky performance score, RT radiotherapy, CRT chemoradiotherapy, G stage grading stage, rT stage recurrent tumor stage, PTV planning target volume